All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2018; the latest 2026-08-26.
From the record
Inhibikase Therapeutics, Inc.'s filings since 2018 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2023-01-24); an auditor change (8-K item 4.01, the latest 2026-08-26) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
5 filed years; profitable in 0 of 5.
From the record
Inhibikase Therapeutics, Inc.'s 5 filed years say what it did: it rose in 2 of 4 years; the deepest fall was 100% from fiscal 2021 to fiscal 2024; net income was positive in 0 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Inhibikase Therapeutics, Inc.'s shareholder treatment is put at 0.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 7% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -28%: lost 28¢ per shareholder dollar. Leverage 5%: owes 5¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Inhibikase Therapeutics, Inc. lost about 28 cents for every dollar of shareholders' money. Leverage: it owed about 5 cents per dollar of assets, and net share issuance: its share count grew 314.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
SI estimate 4.9/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Inhibikase Therapeutics, Inc.'s industry position is put at 4.9 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 102 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are the people in charge doing?
bottom 12% of 110 in its family for leadership; chief executive since 2025.
From the record
Inhibikase Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Iwicki, Mark T (Chief Executive Officer, as filed), filing under that title since 2025-02-19, 1.7 years (bottom 20% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 1.9 years (bottom 1%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 15%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 8.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Inhibikase Therapeutics, Inc.'s room to expand is put at 8.4 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 16% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
top 43% of 100 in its family for growth drivers.
From the record
Inhibikase Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2024: research spending grew 35.3% a year (top 5%); capital spending grew -61.9% a year (bottom 20%) (its annual reports). Inhibikase Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 1.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Inhibikase Therapeutics, Inc.'s expectations vs reality is put at 1.7 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 17% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made